| Update on atopic dermatitis T Torres, E Ferreira, M Gonçalo, P Mendes-Bastos, M Selores, P Filipe Acta medica portuguesa 32 (9), 606-613, 2019 | 251 | 2019 |
| Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study SK Mahil, N Dand, KJ Mason, ZZN Yiu, T Tsakok, F Meynell, B Coker, ... Journal of allergy and clinical immunology 147 (1), 60-71, 2021 | 172 | 2021 |
| JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors M Nogueira, L Puig, T Torres Drugs 80 (4), 341-352, 2020 | 138 | 2020 |
| Nail psoriasis as a predictor of the development of psoriatic arthritis I Raposo, T Torres Actas dermo-sifiliograficas 106 (6), 452-457, 2015 | 120 | 2015 |
| Palmoplantar psoriasis and palmoplantar pustulosis: current treatment and future prospects I Raposo, T Torres American journal of clinical dermatology 17, 349-358, 2016 | 113 | 2016 |
| Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19 Z Izadi, EJ Brenner, SK Mahil, N Dand, ZZN Yiu, M Yates, RC Ungaro, ... JAMA network open 4 (10), e2129639-e2129639, 2021 | 109 | 2021 |
| Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis T Torres, L Puig American Journal of clinical dermatology 19, 23-32, 2018 | 98 | 2018 |
| Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib S Ferreira, E Guttman-Yassky, T Torres American journal of clinical dermatology 21, 783-798, 2020 | 96 | 2020 |
| The protective role of HLA-DRB1 13 in autoimmune diseases A Bettencourt, C Carvalho, B Leal, S Brás, D Lopes, A Martins da Silva, ... Journal of immunology research 2015, 2015 | 90 | 2015 |
| Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study T Torres, L Puig, R Vender, C Lynde, S Piaserico, JM Carrascosa, ... American journal of clinical dermatology 22, 567-579, 2021 | 87 | 2021 |
| JAK/STAT inhibitors for the treatment of atopic dermatitis MA Rodrigues, T Torres Journal of Dermatological Treatment, 2019 | 84 | 2019 |
| Managing cutaneous immune-mediated diseases during the COVID-19 pandemic T Torres, L Puig American Journal of Clinical Dermatology 21 (3), 307-311, 2020 | 79 | 2020 |
| Pediatric psoriasis M Relvas, T Torres American journal of clinical dermatology 18, 797-811, 2017 | 75 | 2017 |
| More than skin deep: the systemic nature of atopic dermatitis C Oliveira, T Torres European Journal of Dermatology 29, 250-258, 2019 | 70 | 2019 |
| A revolutionary therapeutic approach for psoriasis: bispecific biological agents T Torres, M Romanelli, A Chiricozzi Expert opinion on investigational drugs 25 (7), 751-754, 2016 | 69 | 2016 |
| Safety of anti‐TNF therapies in immune‐mediated inflammatory diseases: focus on infections and malignancy R Pereira, P Lago, R Faria, T Torres Drug Development Research 76 (8), 419-427, 2015 | 69 | 2015 |
| Aprepitant: evidence of its effectiveness in patients with refractory pruritus continues T Torres, I Fernandes, M Selores, R Alves, M Lima Journal of the American Academy of Dermatology 66 (1), e14-e15, 2012 | 66 | 2012 |
| Risk of tuberculosis reactivation with interleukin (IL)‐17 and IL‐23 inhibitors in psoriasis–time for a paradigm change M Nogueira, RB Warren, T Torres Journal of the European Academy of Dermatology and Venereology 35 (4), 824-834, 2021 | 62 | 2021 |
| Treatment goals for psoriasis: Should PASI 90 become the standard of care T Torres, L Puig Actas Dermosifiliogr 106 (3), 155-157, 2015 | 61 | 2015 |
| Topical co-delivery of methotrexate and etanercept using lipid nanoparticles: A targeted approach for psoriasis management M Ferreira, L Barreiros, MA Segundo, T Torres, M Selores, SAC Lima, ... Colloids and Surfaces B: Biointerfaces 159, 23-29, 2017 | 54 | 2017 |
